Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
56 results about "Somnolence" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Somnolence (alternatively "sleepiness" or "drowsiness") is a state of strong desire for sleep, or sleeping for unusually long periods (compare hypersomnia). It has distinct meanings and causes. It can refer to the usual state preceding falling asleep, the condition of being in a drowsy state due to circadian rhythm disorders, or a symptom of other health problems. It can be accompanied by lethargy, weakness, and lack of mental agility.
Modified release compositions of milnacipran
A once-a-day oral milnacipran modified release formulation has been developed. The formulation comprises an extended release dosage unit (optionally containing the immediate release portion) coated with delayed release coating. The milnacipran composition, when administered orally, first passes through the stomach releasing from zero to less than 10% of the total milnacipran dose and then enters the intestines where drug is released slowly over an extended period of time. The release profile is characterized by a 0.05-4 hours lag time period during which less than 10% of the total milnacipran dose is released followed by a slow or extended release of the remaining drug over a defined period of time. The composition provides in vivo drug plasma levels characterized by Tmax at 4-10 hours and an approximately linear drop-off thereafter and Cmax below 3000 ng / ml, preferably below 2000 ng / ml, and most preferably below 1000 ng / ml. The composition allows milnacipran to be delivered over approximately 24 hours, when administered to a patient in need, resulting in diminished incidence or decreased intensity of common milnacipran side effects such as sleep disturbance, nausea, vomiting, headache, tremulousness, anxiety, panic attacks, palpitations, urinary retention, orthostatic hypotension, diaphoresis, chest pain, rash, weight gain, back pain, constipation, vertigo, increased sweating, agitation, hot flushes, tremors, fatigue, somnolence, dyspepsia, dysoria, nervousness, dry mouth, abdominal pain, irritability, and insomnia.
Owner:COLLEGIUM PHARMA INC
Pharmaceutical Compositions and Related Methods of Treatment
InactiveUS20080021074A1Decrease and prevent sleepinessDecrease and prevent and lethargyBiocideNervous disorderAdrenergic receptor agonistsClumsiness
Pharmaceutical compositions comprising at least one alpha2-adrenergic agonist or baclofen and at least one alpha1-adrenergic agonist are disclosed. Pharmaceutical compositions comprising tizanidine and modafinil are disclosed. Methods for reducing somnolence, sleepiness, lethargy, dizziness, drowsiness, somnolence, tiredness, lightheadedness, increased weakness, confusion, unsteadiness, clumsiness, or a combination of the symptoms thereof in a human patient; treating pain; and attenuating muscle spasticity, using pharmaceutical compositions comprising at least one alpha2-adrenergic agonist or baclofen and at least one alpha1-adrenergic agonist are disclosed.
Owner:QUESTCOR PHARMA
Pulsatile release compositions of milnacipran
InactiveUS20060003004A1Minimize exposureReduces milnacipran gastrointestinal side effectCapsule deliveryCoatingsPalpitationsPanic
A once-a-day oral milnacipran pulsatile release composition has been developed that releases the drug in spaced apart “pulses”. The dosage forms are comprised of first, second and optional third dosage units, with each dosage unit having a different drug release profile. This dosage form provides in vivo drug plasma levels characterized by Cmax below 3000 ng / ml, preferably below 2000 ng / ml, and most preferably below 1000 ng / ml. The composition provides pulsatile release of milnacipran to produce a therapeutic effect over approximately 24 hours, when administered to a patient in need, resulting in diminished incidence or decreased intensity of common milnacipran side effects such as sleep disturbance, nausea, vomiting, headache, tremulousness, anxiety, panic attacks, palpitations, urinary retention, orthostatic hypotension, diaphoresis, chest pain, rash, weight gain, back pain, constipation, vertigo, increased sweating, agitation, hot flushes, tremors, fatigue, somnolence, dyspepsia, dysoria, nervousness, dry mouth, abdominal pain, irritability, and insomnia.
Owner:COLLEGIUM PHARMA INC
Dry powder formulations of antihistamine for nasal administration
InactiveUS7833550B2Reduce morbidityNot impart bitter tastePowder deliverySenses disorderNasal cavityAzelastine
Dry powder formulations of drugs such as antihistamine for nasal administration are provided where the drug is retained in the nasal cavity, and systemic side effects minimized or eliminated, through the selection of a narrow particle size range, between approximately 10 and 20 microns in diameter. In a preferred embodiment wherein the drug is an antihistamine, retention of the antihistamine at the nasal mucosa is improved and the bitter aftertaste associated with liquid antihistamine formulations significantly reduced. By making a dry powder formulation of an antihistamine (e.g., azelastine) having an average particle size of between 10 and 20 microns, the antihistamine is restricted primarily to the desired target organ, the nasal mucosa. Because the active ingredient stays in the nasal region, a lower dose can be used to achieve the same desired effect. As demonstrated by the examples, this lower dose reduces the incidence of somnolence, and because the active ingredient remains at the target organ and does not accumulate in the back of the throat and mouth, this formulation does not impart a bitter taste.
Owner:MANNKIND CORP
Dry powder formulations of antihistamine for nasal administration
InactiveUS7833549B2Reduce morbidityNot impart bitter tasteBiocidePowder deliveryNasal cavityAzelastine
Owner:MANNKIND CORP
CNS pharmaceutical compositions and methods of use
InactiveUS20110054038A1Eliminate side effectsReduce dependenceBiocideNervous disorderOral medicationSide effect
The present invention is directed to CNS pharmaceutical compositions and methods of use. The pharmaceutical compositions comprise a CNS active agent and preferably at least two vagal neuromodulators, one of which is a mechanoreceptor stimulator. The vagal neuromodulators are preferably in an amount sufficient to reduce a somnolence side-effect of the CNS active agent without changing its therapeutic efficacy / activity. The invention further encompasses a method of reducing CNS active agent side-effects. The method typically comprises oral administration of at least one CNS active agent to a patient at the conventionally accepted dose; and administration of at least two vagal neuromodulators to the patient so that at least one neuromodulator is administered or released from dosage form after the CNS active agent is administered and / or released.
Owner:TARGIA PHARMA
Compositions and methods for enhancing analgesic potency of covalently bound-compounds, attenuating its adverse side effects, and preventing their abuse
InactiveUS20100144645A1Lower potentialAmenable to synthesizing conjugatesBiocideNervous disorderChemical MoietyOpioid antagonist
The invention generally relates to compositions and methods with covalently bound compounds, such as controlled substances covalently attached to a chemical moiety, and opioid antagonists or covalently bound opioid antagonists to enhance analgesic potency and / or attenuate one or more adverse effects of covalently bound compounds, including adverse side effect(s) in humans such as nausea, vomiting, dizziness, headache, sedation (somnolence), physical dependence or pruritis. This invention relates to compositions and methods for selectively enhancing the analgesic potency of a covalently bound compound and simultaneously attenuating anti-analgesia, hyperalgesia, hyperexcitability, physical dependence and / or tolerance effects associated with the administration of a covalently bound compound. The methods of the invention comprise administering to a subject an analgesic or sub-analgesic amount of a covalently bound compound and an amount of excitatory opioid receptor antagonist such as naltrexone or nalmefene effective to enhance the analgesic potency of a covalently bound compound and attenuate the anti-analgesia, hyperalgesia, hyperexcitability, physical dependence and / or tolerance effects of covalently bound compound. The invention also relates to the addition of covalently-bound opioid antagonists to the compositions containing covalently bound compounds such that if the compositions are subjected to manipulation by illicit chemists, the opioid antagonist is released effectively reducing or eliminating the euphoric effect of the covalently bound compounds.
Owner:SHIRE PLC
CNS pharmaceutical compositions and methods of use
ActiveUS20140256709A1Eliminate side effectsReduce dependenceBiocideNervous disorderSide effectOral medication
The present invention is directed to CNS pharmaceutical compositions and methods of use. The pharmaceutical compositions comprise a CNS active agent and preferably at least two vagal neuromodulators, one of which is a mechanoreceptor stimulator. The vagal neuromodulators are preferably in an amount sufficient to reduce a somnolence side-effect of the CNS active agent without changing its therapeutic efficacy / activity. The invention further encompasses a method of reducing CNS active agent side-effects. The method typically comprises oral administration of at least one CNS active agent to a patient at the conventionally accepted dose; and administration of at least two vagal neuromodulators to the patient so that at least one neuromodulator is administered or released from dosage form after the CNS active agent is administered and / or released.
Owner:TARGIA PHARMA
CNS pharmaceutical compositions and methods of use
InactiveUS8729070B2Eliminate side effectsReduce dependenceBiocideNervous disorderOral medicationSide effect
Owner:TARGIA PHARMA
Chinese medicinal composition for curing somnolence and preparation method thereof
InactiveCN101890142AImprove self-coordinationEffective treatmentNervous disorderMammal material medical ingredientsSleep paralysisSalvia miltiorrhiza
The invention discloses a novel Chinese medicinal composition for curing somnolence and a preparation method thereof. The Chinese medicinal composition mainly comprises the following raw material medicaments: tangerine peel, immature bitter orange, raw raidx astragali, white paeony root, Chinese angelica, common yam rhizome, campanumaea pilosula, ginseng, motherwort herb, storax, nutgrass galingale rhizome, camphor, Szechwan Chinaberry Fruit, chrysanthemum, salvia miltiorrhiza bunge, fineleaf schizonepeta herb, divaricate saposhnikovia root, incised notopterygium rhizome, medicated leaven, malt, radish seed, peach seed, safflower, south dodder seed, twotooth achyranthes root and the like. The Chinese medicinal composition can be prepared into any common oral preparation by the conventional Chinese medicinal preparation method. The Chinese medicinal composition can obviously improve symptoms such as somnolence, drowsiness, cataplexy, sleep paralysis, hypnoagogic hallucination and the like. The Chinese medicinal composition has the advantages of exact clinical effect, obvious curative effect, quick response, low cost, basically no toxic or side effect and the like because the Chinese medicinal composition is basically combined by edible and pharmaceutical medicaments specified in national formulary.
Owner:TAIYI HEPU BEIJING RES INST OF TCM
Heart fire-clearing upset-relieving health-care tea and preparation method thereof
The invention provides a heart fire-clearing upset-relieving health-care tea, which is characterized by being prepared from the following materials: Chinese angelica, szechuan lovage rhizome, prepared rehmannia root, turmeric root-tuber, rhizoma zingiberis preparatum, red peony root, white paeony root, peach seed, carthamus, thinleaf milkwort root-bark, lotus leaf, semen nelumbinis, mix-fried licorice, Chinese date and ginkgo seed. The preparation method comprises the following steps: cleaning the raw materials; mixing the cleaned raw materials; adding water into the mixture; after boiling the mixture for 20 to 60 minutes, filtering to remove slag and obtaining the heart fire-clearing upset-relieving health-care tea. In the tea, the raw materials jointly exert effects of promoting qi circulation and removing obstruction in the collateral, clearing heart and inducing resuscitation, activating blood and dissolving stasis and warming inside and relieving pains, so the tea can treat sadness, palpitation due to fright, mind absence, somnolence, poor memory, stagnation of the liver-qi, and qi stagnation and blood stasis. The tea can be drunk directly after being boiled, has health-care function, and can relieve long-term depression, ease mind, and be used as a daily health-care product.
Owner:周大红
Enzyme cofactor combination for supplementing pyruvate dehydrogenase and alpha ketogluterate dehydrogenase complexes
The present invention provides a method and pharmaceutical composition for preventing or treating the development of syndromes related to dysfunctional energy metabolism, such as neuropathy, spontaneous nocturnal muscle cramps associated with neuropathy, seizuring, diabetes mellitus; pediatric hypoglycemia; myopathy; muscle fatigue; muscle spasms; somnolence; reduced mental acuity; exercise intolerance and myocardial insufficiency, which are due to cofactor deficiencies associated with the pyruvate dehydrogenase complex and the alpha-ketogluterate dehydrogenase (a-ketogluterate dehydrogenase) complex in humans or other mammals in need thereof. In particular, a method of preventing or treating at least one syndrome related to defective glucose metabolism in humans or other mammals is provided comprised of administering a combination of enzyme cofactors containing therapeutically effective amounts of thioctic acid, niacinamide, pantothenate, riboflavin and thiamine. Also provided is a pharmaceutical composition comprised of a carrier and the combination of cofactors.
Owner:HOWARD JAMES R
Dry powder formulations of antihistamine for nasal administration
InactiveUS20080038358A1Reduce morbidityNot impart bitter tastePowder deliveryBiocideSide effectAzelastine
Dry powder formulations of drugs such as antihistamine for nasal administration are provided where the drug is retained in the nasal cavity, and systemic side effects minimized or eliminated, through the selection of a narrow particle size range, between approximately 10 and 20 microns in diameter. In a preferred embodiment wherein the drug is an antihistamine, retention of the antihistamine at the nasal mucosa is improved and the bitter aftertaste associated with liquid antihistamine formulations significantly reduced. By making a dry powder formulation of an antihistamine (e.g., azelastine) having an average particle size of between 10 and 20 microns, the antihistamine is restricted primarily to the desired target organ, the nasal mucosa. Because the active ingredient stays in the nasal region, a lower dose can be used to achieve the same desired effect. As demonstrated by the examples, this lower dose reduces the incidence of somnolence, and because the active ingredient remains at the target organ and does not accumulate in the back of the throat and mouth, this formulation does not impart a bitter taste.
Owner:MANNKIND CORP
Methylphenidatefrozen dry powder preparation for injection and preparation process thereof
InactiveCN101683342AEliminate drowsinessEliminate burnoutOrganic active ingredientsPowder deliveryDaytime somnolenceHyperkinetic syndrome
The invention relates to a methylphenidatefrozen dry powder preparation for injection and a preparation process thereof; the preparation takes the salt of the methylphenidatefrozen as drug constituents and forms the drug composite by mixing acceptable accessories pharmaceutically; the preparation method is that: the salt of the methylphenidatefrozen is taken as raw material, the accessories with specific kinds and proportion are added, and the dry powder preparation for intravenous injection is prepared and developed by adopting the illustrative technological measures. The dry powder preparation is used for treating attention deficiency hyperkinetic disorder (hyperkinetic syndrome of children and mild brain functional maladjustment), and eliminating somnolence, lassitude and respiratory depression caused by soporifics.
Owner:STAR LAKE BIOSCI CO INC ZHAOQING GUANGDONG
American cockroach medicinal composition for curing gastritis and peptic ulcers and preparation method thereof
InactiveCN101837023AGood curative effectEasy to prepareOrganic active ingredientsAnthropod material medical ingredientsDiseaseBULK ACTIVE INGREDIENT
The invention discloses an American cockroach medicinal composition for curing gastritis and peptic ulcers. The medicinal composition is mainly prepared from an active ingredient mixture prepared by mixing an American cockroach extract and omeprazole. The weight part ratio of the American cockroach extract to the omeprazole is equal to 0.8-1.2g: 0.33-80mg. A preparation method of the American cockroach medicinal composition for curing the gastritis and the peptic ulcers comprises the following steps of: preparing the American cockroach extract, mixing active ingredients, and preparing medicaments. The medicinal composition has simple preparation method, fully exerts effects of the American cockroach extract, and effectively improves curative effects on the gastritis and the peptic ulcers. The American cockroach medicinal composition has no responses such as headache, diarrhea, astriction, stomachache, sicchasia, emesis skin eruption, dizziness, somnolence and insomnia and the like, and basically does not increase transaminase or bilirubin.
Owner:耿福能
Method for inhibiting melatonin secretion by light source and lighting device
The invention provides a method for inhibiting melatonin secretion by using a light source. According to the method, a lighting device is specially designed to emit lighting light having a specific wavelength within the wavelength range of 581nm and 590nm, and various experimental data have proved that the lighting light can be used to serve as a melatonin secretion inhibitor. Therefore, the experimental data have proved that the lighting device of the invention is suitable for being used for light therapy for winter depression, thereby treating the seasonal affective disorder (namely the winter depression) by inhibiting the melatonin secretion. Briefly speaking, after a patient suffering from the winter depression receives a treatment course of the light therapy with the lighting light with the wavelength range of 581-590nm, the symptoms of the winter depression, including somnolence, emotional disorder and the like, of the patient suffering from the winter depression can be cured finally due to the fact that the patient has a good mental state and a stable emotional state.
Owner:周卓煇
Method of treating the chemotoxic effects of chemotherapeutic drugs on brain tissue
This invention is related to a novel method of treating the chemotoxic effects on the central nervous system of chemotherapeutic drugs, namely Adriamycin, by administering a therapeutically effective amount of anti-Tumor Necrosis Factor-α antibody to a patient to alleviate the symptoms of the effects. The antibody operates to decrease the serum level of Tumor Necrosis Factor-α, prevents the p53 translocation to mitochondria and prevents the decline in mitochondrial respiration of brain tissues and thereby relieves the symptoms of somnolence caused by chemotherapeutic drugs.
Owner:UNIV OF KENTUCKY RES FOUND
Use of ferulic acid in preparation of drug for resisting mammal anxiety
InactiveCN104083349ASignificant anxiolytic effectNo sedationOrganic active ingredientsNervous disorderSide effectAnti-Anxiety Effect
The invention provides a use of ferulic acid in preparation of a drug for resisting mammal anxiety and provides a novel antianxiety drug having good effects and small side effects. Ferulic acid is an effective component of the antianxiety drug. Results of mouse elevated plus-maze test, hole-board test and spontaneous activity test on ferulic acid shows that ferulic acid has substantial antianxiety effects and no calmness effect and thus adverse reactions such as fatigue and somnolence caused by calmness effects of the existing antianxiety drug are avoided.
Owner:BEIJING UNIV OF CHINESE MEDICINE
CNS pharmaceutical compositions and methods of use
ActiveUS9579299B2Eliminate side effectsLow toxicityNervous disorderInorganic active ingredientsSide effectActive agent
The present invention is directed to CNS pharmaceutical compositions and methods of use. The pharmaceutical compositions comprise a CNS active agent and preferably at least two vagal neuromodulators, one of which is a mechanoreceptor stimulator. The vagal neuromodulators are preferably in an amount sufficient to reduce a somnolence side-effect of the CNS active agent without changing its therapeutic efficacy / activity. The invention further encompasses a method of reducing CNS active agent side-effects. The method typically comprises oral administration of at least one CNS active agent to a patient at the conventionally accepted dose; and administration of at least two vagal neuromodulators to the patient so that at least one neuromodulator is administered or released from dosage form after the CNS active agent is administered and / or released.
Owner:TARGIA PHARMA
Kidney-tonifying, collateral-dredging and brain-nourishing paste and preparation method thereof
InactiveCN108042766ASymptoms improvedSigns improvedSenses disorderNervous disorderAmnesiaSpermatorrhea
The invention discloses kidney-tonifying, collateral-dredging and brain-nourishing paste and a preparation method thereof. The kidney-tonifying, collateral-dredging and brain-nourishing paste is characterized by being prepared from the following crude drugs: radix rehmanniae preparata, rhizoma dioscoreae, fructus corni, poria cocos, cortex moutan, rhizoma alismatis, fructus lycii, semen cuscutae,ganoderma lucidum, fructus ligustri lucidi, herba ecliptae, fructus mori albae, mantidis ootheca, fructus alpiniae oxyphyllae, raw radix astragali seu hedysari, radix polygonati officinalis, lily bulb, semen persicae, safflower, red paeony root, rhizoma chuanxiong, radix bupleuri, fried fructus aurantii, radix achyranthis bidentatae, radix platycodonis, rhizoma anemones altaicae, prepared radix polygalae, rhizoma atractylodis, bighead atractylodes rhizome, semen nelumbinis, scorched fructus crataegi, medicated leaven, fried rice sprout, fried malt, pericarpium citri reticulatae, radix curcumae, radix clematidis, Chinese angelica root, processed rhizoma pinelliae, fructus liquidambaris, radix et rhizoma salviae miltiorrhizae, fructus amomi, American ginseng, syngnathus, hippocampus, tortoise-plastron glue, turtle shell glue, radix notoginseng, bulbus fritillariae cirrhosae, sugar and yellow rice wine. The kidney-tonifying, collateral-dredging and brain-nourishing paste is used for treating kidney insufficiency and essence deficiency, qi and blood deficiency, dizziness and tinnitus caused by stagnation of phlegm and blood stasis, insomnia and dreaminess, amnesia and somnolence, waistsoreness and limp legs, spermatorrhea and premature ejaculation, sterility infertility, hypertension, stroke sequelae, senile dementia, Parkinson's disease, paralysis agitans, multiple sclerosis andthe like, and also can be used for premature senility of middle-aged people or weakness of old people and the like.
Owner:RIZHAO HOSPITAL OF TCM
Peony extract-methotrexate composition, preparation method thereof and use thereof
InactiveCN101926860AEffective in treating rheumatoidReduce or avoid liver damageOrganic active ingredientsAntipyreticTreatment effectMedicine
The invention provides a peony extract-methotrexate composition, a preparation method thereof and use thereof. The peony extract-methotrexate composition is prepared from a peony extract and methotrexate and has a better rheumatoid treatment effect than methotrexate and the mixture of the methotrexate and total glucosides of paeony. Meanwhile, the composition can reduce or avoid adverse reactions caused by the methotrexate, such as liver damage, somnolence, inappetence and the like.
Owner:NINGBO LIWAH PHARM CO LTD
Medicine for clearing heat and calming nerves and preparation method thereof
InactiveCN102247527AHigh content of active ingredientsReduce dosageHeavy metal active ingredientsNervous disorderSalvia miltiorrhizaCelastrus orbiculatus
Owner:LIAONING HUAXIN PHARMA
A manufacturing method for a nerves-soothing and hair-cleaning health care pillow towel
The invention provides a manufacturing method for a nerves-soothing and hair-cleaning health care pillow towel and belongs to the field of processing of household bed textile articles. A common pillow towel is treated with a health care solution prepared from polygala tenuifolia, bulbus lilii, platycladi seeds and rhizoma atractylodis, is then treated with a health care solution prepared by adding chamomile flower essence oil, and is finally treated with a health care solution prepared by adding tea saponin, and thus the finished product is obtained. The pillow towel can remarkably improve the quality of sleep, can soothe nerves, promote intelligence, promote brain metabolism, maintain beauty and keep people young, and improve eyesight, is helpful for the therapy of insomnia and dreamful sleep, night sweat and spontaneous perspiration, laziness and somnolence, and heavy pain of the head and body, and has the functions of loosening hair, removing dandruff and relieving itching and achieving the effects of cleaning hair and protecting hair.
Owner:庆阳凌云服饰集团有限公司
Spleen-Qi-nourishing and dampness-removing particles containing effective traditional Chinese medicinal ingredients, and preparation method thereof
ActiveCN106729190AImprove sleepingEliminates dampness and resolves phlegmNervous disorderDigestive systemSucroseAdditive ingredient
The invention provides spleen-Qi-nourishing and dampness-removing particles containing effective traditional Chinese medicinal ingredients, and a preparation method thereof. The particles contain lotus leaf extracts, yam extracts, poria cocos extracts, burdock root extracts, eucommia ulmoides extracts, hawthorn extracts, semen coicis extracts, red bean extracts, red dates extracts, roasted malt extracts, soluble starch, sucrose, dextrin, distilled water and 75% ethyl alcohol. Compared with the prior art, the spleen-Qi-nourishing and dampness-removing particles contain multiple effective traditional Chinese medicinal ingredients, and can be used for nourishing Qi and spleen, removing dampness, resolving phlegm, conditioning a phlegm-damp type body, eliminating local edema, and improving symptoms of hyperhidrosis, profuse sputum, tiredness and somnolence caused by insufficiency of the spleen; the spleen is nourished whilst water dampness is removed.
Owner:WANNAN MEDICAL COLLEGE
Anti-motion sickness drug
InactiveCN106492159AQuickly relieve dizzinessQuick relief of nauseaDigestive systemPlant ingredientsSide effectCarsickness
The invention discloses an anti-motion sickness drug. The anti-motion sickness drug is prepared from, by weight, 20-40 parts of fresh ginger, 5-8 parts of fructus amomi, 10-18 parts of orange peel, 20-30 parts of chrysanthemum, and 7-15 parts of wild jujube. The anti-motion sickness drug is greatly featured by effectively eliminating coordinate dyskinesia, and preventing carsickness, seasickness and airsickness by taking before taking transportation tools; the anti-motion sickness drug can rapidly release giddy, nausea, emesis and other symptoms of a patient by taking it when the sick occurs, and recover health. The anti-motion sickness drug is free from side effects such as somnolence, sleepy, fatigue and the like; moreover, the drug is simple in production process, low in price, low in manufacturing cost, and simple in preparation, and so on.
Owner:韦玉姣
Wind and cold dispelling walnut oil
InactiveCN105028697AHas the effect of expelling wind and coldReasonable workmanshipEdible oils/fatsLicorice rootsAconite Root
A wind and cold dispelling walnut oil is prepared from, by weight, 250-260 parts of Juglans cathayensis Dode var. formosana (Hayata) A. et R.H.Chang, 30-40 parts of flaxseed, 70-80 parts of Zanthoxylum armatum DC., 50-60 parts of coconut shell, 60-100 parts of unprepared aconite root, 30-40 parts of dry ginger and 40-50 parts of honey-fried licorice root. Zanthoxylum armatum DC. added in the preparation process has wind and cold dispelling effects, aconite root is highly acrid and highly hot, belongs to human heart, spleen and kidney meridians, and can warm kidney, strengthen yang, dispel cold and rescue collapse, dry ginger is acrid and hot, belongs to lung, spleen and heart meridians, and can warm middle, dispel cold, support yang and promote lactation, and dry ginger and aconite root complement each other, and have large yang supporting and cold dispelling effects, so aconite root is not hot if no dry exists; and honey-fried licorice root is warm in nature, warms internal organs, can tonify spleen and stomach to condition many drugs, and can alleviate dry, strong, hot and cold properties of ginger and aconite root, so the walnut oil realizes yin breaking and yang restoration, has no dissipation waste, and is suitable for being eaten by medium Jiao deficiency cold people with rheumatism, cold limbs, cold aversion curling, spirit weakness somnolence, pale complexion, stomachache dysentery and diarrhea.
Owner:ANQING XIAOZHU FOOD TECH CO LTD
Traditional Chinese medicine health tea
InactiveCN108029819ANormal metabolismWith qi and depressionTea substituesSide effectAdditive ingredient
The invention discloses traditional Chinese medicine health tea. The traditional Chinese medicine health tea is prepared from the following raw materials in parts by weight: 50-70 parts of roses, 50-70 parts of jasmine flowers, 50-70 parts of seville orange flowers, 50-70 parts of lotus leaves, 30-50 parts of wolfberry fruits and 5-20 parts of dried orange peel. The traditional Chinese medicine health tea adopts common medicinal and edible traditional Chinese medicines as raw materials, is safe and reliable, has no toxic and side effects and no injury to the digestive system and the absorptionsystem of a human body, can give full play to medicinal effects of every traditional Chinese medicine component by compatible application of the raw materials and has the efficacies of beautifying skin, reducing lipid, producing a refreshing effect, regulating the flow of qi, relieving stagnation, resolving phlegm and removing dampness by diuresis. Honey in the traditional Chinese medicine healthtea is mainly used for flavoring and added on the preference of drinkers. The traditional Chinese medicine health tea is capable of promoting normal metabolism of a human body, has obvious weight reducing effects and also has good efficacies of regulating the flow of qi, relieving stagnation, resolving phlegm and removing dampness by diuresis on patients who have fatty liver disease due to accumulation of phlegm-dampness in the body and have the following clinical manifestations: fat body, dull pain in chest and hypochondrium, dizziness, choking sensation in chest, somnolence, tiredness and the like.
Owner:河南明珍方医药科技有限公司
Traditional Chinese medicine for treating somnolence disease caused by dampness encumbering the spleen
InactiveCN104367910ARelieve symptomsSymptoms disappearedPowder deliveryNervous disorderDiseaseTherapeutic effect
The invention discloses a traditional Chinese medicine for treating a somnolence disease caused by dampness encumbering the spleen. The traditional Chinese medicine is characterized by being prepared from the following raw materials in parts by weight: 12 parts of hedychium spicatum, 8 parts of berberis soulieana, 10 parts of root of compact incarvillea, 15 parts of quercus fabri hance, 15 parts of Pseudostellaria, 12 parts of punctatelip woodbetony flower, 15 parts of wild chervil, 15 parts of mahonia bealei carr, 12 parts of flatstem milkvetch seed, 10 parts of Pu'er tea, 15 parts of bushy dasiphora flower, 12 parts of radix fici simplicissimae root, 3 parts of phytolacca flower, 20 parts of stellaria yunnanensis, 12 parts of ginseng flower and 6 parts of liquorice. The prepared traditional Chinese medicine disclosed by the invention has the efficacies of drying dampness and strengthening the spleen, and inducing resuscitation, and is capable of treating both symptoms and root causes of the somnolence disease caused by dampness encumbering the spleen, and fundamentally treating the disease. Use of a plurality of cases of such patients over the years shows that the effective rate reaches 100%, the efficiency reaches 100%, the recovery rate reaches 97.5%; the treatment effect is good; and the somnolence disease does not recur after being cured.
Owner:青岛祥翔生物医药科技有限公司
Ophthalmic anti-somnolence lens, device and method
ActiveUS10048515B2Improved estheticImprove eyesightSpectales/gogglesNon-optical adjunctsDaytime somnolenceEngineering
The ophthalmic lens includes a substrate, the substrate having a rear face and a front face, and at least one external interferential coating, the at least one interferential coating being such that it enables to selectively reflect light arriving on the rear face with a local maximum of reflection of at least 10% for a wavelength within the range between 450 nm and 490 nm.
Owner:ESSILOR INT CIE GEN DOPTIQUE
Middle-aged and elderly health-care food for improving sleep and protecting eyesight and preparation method thereof
ActiveCN104886574AImprove blurDizziness noNatural extract food ingredientsFood ingredient functionsBlurred visionGanoderma atrum
The invention belongs to the technical field of food, and in particular relates to a middle-aged and elderly health-care food for improving sleep and protecting eyesight and a preparation method thereof. The formula of the middle-aged and elderly health-care food for improving sleep and protecting eyesight comprises the following components by weight percent: 5-10 percent of xanthophyll, 20-50 percent of Ganoderma atrum extract, 1-5 percent of melatonin and 20-50 percent of grassleaf sweelflag rhizome extract. The formula is scientific and reasonable, has the functions of calming the mind and nerves, relieving anxiety, promoting sleep, and improving sleep quality, and can not cause dizzness, somnolence and addiction which are caused by common drugs after awaking. In addition, the health-care food also has the effects of relieving asthenopia and hypopsia caused by insomnia, improving blurred vision and protecting the eyesight.
Owner:南京贝杉国际贸易有限公司
Popular searches
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com